Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Influenza

Free Subscription Articles published in Drug Saf Retrieve available abstracts of 26 articles: HTML format

Single Articles

September 2021
1. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
   Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
   Drug Saf. 2021;44:987-998.
   PubMed     Abstract available
   
   
   
2. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
   NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
   Drug Saf. 2021;44:929-938.
   PubMed     Abstract available
   
   
   June 2021
3. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
   Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
   Drug Saf. 2021;44:635-644.
   PubMed     Abstract available
   
   
   April 2021
4. DASGUPTA N
   Safety Consequences of Off-Label Drugs Used for COVID-19.
   Drug Saf. 2021;44:399-402.
   PubMed    
   
   
   
5. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
   French Pharmacovigilance Public System and COVID-19 Pandemic.
   Drug Saf. 2021;44:405-408.
   PubMed     Abstract available
   
   
   February 2021
6. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
   Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
   Drug Saf. 2021;44:255-257.
   PubMed    
   
   
   January 2021
7. BEYZAROV E, Chen Y, Julg R, Naim K, et al
   Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
   Drug Saf. 2021;44:95-105.
   PubMed     Abstract available
   
   
   
8. SHAKIR S, Lane S, Davies M
   How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
   Drug Saf. 2021;44:1-5.
   PubMed    
   
   
   December 2020
9. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
   Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
   Drug Saf. 2020;43:1315-1322.
   PubMed     Abstract available
   
   
   
10. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    PubMed     Abstract available
    
    
    
11. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    PubMed     Abstract available
    
    
    
12. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    PubMed     Abstract available
    
    
    August 2020
13. OSBORNE V, Davies M, Lane S, Evans A, et al
    Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:809-821.
    PubMed     Abstract available
    
    
    
14. SULTANA J, Cutroneo PM, Crisafulli S, Puglisi G, et al
    Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
    Drug Saf. 2020;43:691-698.
    PubMed     Abstract available
    
    
    
15. TUCCORI M, Convertino I, Ferraro S, Cappello E, et al
    The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
    Drug Saf. 2020;43:699-709.
    PubMed     Abstract available
    
    
    July 2020
16. MOORE N, Carleton B, Blin P, Bosco-Levy P, et al
    Does Ibuprofen Worsen COVID-19?
    Drug Saf. 2020;43:611-614.
    PubMed    
    
    
    
17. OLRY A, Meunier L, Delire B, Larrey D, et al
    Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.
    Drug Saf. 2020;43:615-617.
    PubMed    
    
    
    
18. MONTASTRUC JL, Toutain PL
    A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
    Drug Saf. 2020;43:657-660.
    PubMed     Abstract available
    
    
    
19. DAVIES M, Osborne V, Lane S, Roy D, et al
    Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:645-656.
    PubMed     Abstract available
    
    
    June 2020
20. CHANDLER RE, McCarthy D, Delumeau JC, Harrison-Woolrych M, et al
    The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic.
    Drug Saf. 2020;43:511-512.
    PubMed    
    
    
    
21. TRIFIRO G, Crisafulli S, Ando G, Racagni G, et al
    Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
    Drug Saf. 2020;43:507-509.
    PubMed    
    
    
    May 2020
22. MOORE N
    Chloroquine for COVID-19 Infection.
    Drug Saf. 2020;43:393-394.
    PubMed    
    
    
    December 2019
23. DOS SANTOS G, Nguyen BY, Damaso S, Godderis L, et al
    Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Drug Saf. 2019 Dec 28. pii: 10.1007/s40264-019-00893.
    PubMed     Abstract available
    
    
    October 2017
24. NIGWEKAR PV, Kumar A, Padbidri VV, Choudhury A, et al
    Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.
    Drug Saf. 2017 Oct 12. doi: 10.1007/s40264-017-0605.
    PubMed     Abstract available
    
    
    April 2017
25. DOS SANTOS G, Seifert HA, Bauchau V, Shinde V, et al
    Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt.
    Drug Saf. 2017 Apr 17. doi: 10.1007/s40264-017-0532.
    PubMed     Abstract available
    
    
    December 2016
26. MORO P, Baumblatt J, Lewis P, Cragan J, et al
    Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
    Drug Saf. 2016.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: